Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycated haemoglobin as a dual biomarker

Biomedical Research

Volumn 22, Issue 3, 2011, Pages 375-380

  Vinodmahato, Ram ^a   Gyawali, Prajwal ^b   Raut, Pramod Psd ^c   Regmi, Prashant ^b   Singh, Khelanand Psd ^b   Pandeya, Dipendra Raj ^d   Gyawali, Prabin ^e  

^a Peoples Dental College and Hospital   (Nepal)

^b TRIBHUVAN UNIVERSITY   (Nepal)

^c CIVIL SERVICE HOSPITAL   (Nepal)

^d Department of Microbiology and Immunology   (South Korea)

^e Department of Medicine   (Nepal)

Author keywords

Biomarker; Diabetes mellitus; Dyslipidemia; Glycated hemoglobin; Lipid profile panel

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; SEX DIFFERENCE; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79960792701     PISSN: 0970938X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Diabtes.http://who.int/mediacentre/factsheets/fs312/en/index.html (Updated on November 2009).
2. Glycosylaed Haemoglobin, HbA1C.hptt://clinlabnavi-gator.com/test-interpretations/haemoglobin-a1c.html?letter=h (Updated on 18 June 2010).
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
4. Windler E. What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome? Atheroscler Suppl 2005;6: 11-14.
5. Marshall SM and Barth JH. Standardization of HbA1c measurements - a consensus statement. Diabetic Medi-cine 2000; 17:5-176.
6. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosy-lated hemoglobin and cardiovascular disease in diabe-tes mellitus. Ann Intern Med 2004; 14: 421-431.
7. Khaw KT, Wareham N, Bingham S, Luben R, Welch A and Day N. Association of hemoglobin A1c with car-diovascular disease and mortality in adults: the Euro-pean Prospective Investigation into Cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
8. Hill JB, Kessler G. An automated determination of glucose utilizing a glucose oxidase-peroxidase system. J Lab Clin Med 1961; 57: 970-980.
9. Deeg R, Ziegenhorn J. Kinetic enzymatic method for automated determination of total cholesterol in serum. Clin Chem 1983; 29: 1798-802.
10. Bucolo G, David H. Quantitative determination of se-rum triglycerides by the use of enzymes. Clin Chem 1973; 19: 476-482.
11. Assmann G, Schriewer H, Schmitz G, Hägele EO. Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem 1983; 29: 2026-2030.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein choles-terol in plasma without use of the preparative ultracen-trifuge. Clin Chem 1972; 18: 499-502.
13. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [spe-cial communication]. JAMA 2001; 285:2486- 2497.
14. American Diabetes Association. Diagnosis and classifi-cation of Diabetes Mellitus. Diabetes Care 2010; 33:s62-s69.
15. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005; 28: 514-520.
16. Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabe-tes Care 2005; 28: 2472-2479.
17. Sibley SD, Thomas W, de Boer I, Brunzell JD, Steffes MW. Gender and elevated albumin excretion in the Diabetes Control and Complications trial/ Epidemiol-ogy of Diabetes Interventions and Complications (DCCT/EDIC) cohort: role of central obesity. Am J Kidney Dis 2006; 47: 223-232.
18. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996; 37: 693-707.
19. Tavangar K, Murata Y, Pedersen ME, Goers JF, Hoff-man AR, Kraemer FB. Regulation of lipoprotein lipase in the diabetic rat. J Clin Invest 1992; 90: 1672-1678.
20. Regmi P, Gyawali P, Shrestha R, Sigdel M, Mehta KD, Majhi S. Pattern of Dyslipidemia in Type 2 Dia-betic Subjects in Eastern Nepal. JNAMLS 2009; 10: 11-13.
21. Ito C, Maeda R, Ishida S, Sasaki H, Harada H. Correla-tion among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Res Clin Pract 2000; 50: 225-230.
22. Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, et al. Glycated hemoglobin and cardiovascular risk fac-tors in Chinese subjects with normal glucose tolerance. Diabet Med 1998;15: 573-578.
23. Rosediani M, Azidah AK, Mafauzy M. Correlation between fasting plasma glucose, post prandial glucose and glycated haemoglobin and fructosamine. Med J Malaysia 2006; 61: 67-71.
24. Erciyas F, Taneli F, Arslan B, Uslu Y. Glycemic con-trol, oxidative stress and lipid profile in children with type 1 Diabetes Mellitus. Arch Med Res 2004; 35:134-140.
25. Andersen GE, Christiansen JS, Mortensen HB, Christiansen KM, Predersen-Bjerguard L, Kastrup KW, et al. Plasma lipid and lipoprotein in type 1 diabetic children and adolescent in relation to metabolic regula-tion,obesity and genetic hyperlipoprotenimia. Actu paediator Scand 1983; 72: 361-365.
26. Ohta T, Nishiyama S, Nakamura T, Saku K, Maung KK, Matsuda I. Predominance of large low density lipoprotein particles and lower fractional esterification rate of cholesterol in high density lipoprotein in chil-dren with insulin-dependent diabetes mellitus. Eur J Pediatr 1998; 157: 276-281.
27. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003; 26: 16-23.
28. Gimeno-Orna JA, Faure-Nogueras E and Sancho-Serrano MA. Usefulness of total cholesterol/HDL-cholesterol ratio in the management of diabetic dyslipi-daemia. Diabet Med 2005; 22: 26-31.
29. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, et al. Total cholesterol /HDL cholesterol ratio vs LDL cholesterol /HDL cholesterol ratio as in-dices of ischemic heart disease risk in men. The Que-bec Cardiovascular Study. Arch Intern Med 2001; 161: 2685-2692.
30. Peters AL. Clinical relevance of non-HDL cholesterol in patients with diabetes. Clinial Diabetes 2008;26:3-7.
31. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship be-tween plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Com-plications trial. Diabetes Care 2002; 25: 275-278.
32. Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med 2007; 7: 24-29.
33. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2006; 29: 877-882.
34. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Pro-spective Investigation of Cancer and Nutrition (EPIC-Norfolk). Br Med J 2001; 322: 15-18.